论文部分内容阅读
目的观察单用胰岛素治疗2型糖尿病效果不佳时,加用盐酸吡格列酮后疗效及安全性。方法将60例2型糖尿病患者在应用诺和灵30R治疗基础上,加用盐酸吡格列酮15 mg/d,顿服。共12周,比较治疗前、后FPG、PPG、HbA-Ic、ALT、AST、TBIL、BUN、Cr、UAE并进行统计学分析。结果与治疗前相比治疗1周后FPG、PPG、均显著下降(P<0.01);第12周后HbAIc有显著下降(P<0.01),而ALT、AST、TBIL、BUN、Cr、UAE均无明显变化(P>0.05);治疗第12周后,平均全日胰岛素总量比治疗前减少了23.5%。结论盐酸吡格列酮具有降低胰岛素抵抗,提高胰岛素敏感性,保护B细胞分泌功能作用。对肝、肾无明显毒副作用,安全性较高。
Objective To observe the curative effect and safety of single insulin treatment of type 2 diabetes mellitus after adding pioglitazone hydrochloride. Methods Sixty patients with type 2 diabetes were treated with Novolin 30R plus pioglitazone hydrochloride 15 mg once daily. A total of 12 weeks. FPG, PPG, HbA-Ic, ALT, AST, TBIL, BUN, Cr and UAE before and after treatment were compared and statistically analyzed. Results Compared with those before treatment, the levels of FPG and PPG were significantly decreased (P <0.01), and the levels of HbAIc were significantly decreased after 12 weeks of treatment (P <0.01), while the levels of ALT, AST, TBIL, BUN, Cr and UAE There was no significant change (P> 0.05). After the 12th week of treatment, the average total daily insulin volume decreased by 23.5% compared with that before treatment. Conclusion Pioglitazone hydrochloride has the effects of reducing insulin resistance, improving insulin sensitivity and protecting B cell secretory function. On the liver, kidney no obvious side effects, higher safety.